BioNTech acquires Eufets

Published: 5-Jun-2009
Media Ingredients Pharmaceutical

German biotech company BioNTech has acquired Eufets from Fresenius Biotech. Eufets is a GMP and GLP services specialist and under its new owner will retain all facilities, staff and contracts of the former company.


German biotech company BioNTech has acquired Eufets from Fresenius Biotech. Eufets is a GMP and GLP services specialist and under its new owner will retain all facilities, staff and contracts of the former company.

"The investment in Eufets is an excellent fit, endowing BioNTech with synergistic platforms and complementary expertise," said Dr Ugur Sahin, ceo of BioNTech.

The company said it would progress Eufets into a centre of excellence by developing and providing high-quality GMP/GLP services for recombinant vaccines, cell based therapies, gene- and immunotherapies.

Helmut Jeggle, chair of the supervisory board of BioNTech added: "The acquisition of Eufets is a logical step for our long-term strategy to build an excellent and competitive company for biopharmaceutical drug and biomarker development."

BioNTech is a "spin-off"-company of the Johannes Gutenberg University in Mainz, Germany.

  • Companies:
  • Fresenius-Kabi
  • BioNTech AG
See more

You may also like

Regulatory

Fresenius Kabi receives approval for tocilizumab biosimilar Tyenne

Read more
The Interleukin-6 antagonist can be used to treat various inflammatory and immune mediated conditions

Trending Articles

  1. Transmission Raman Spectroscopy - access the webinar series today Offering significant advantages for bulk, quantitative and non-destructive analysis, Transmission Raman Spectroscopy is a preferred choice for applications where surface analysis is insufficient or prone to errors. Speakers from Agilent, Novartis Pharma, AstraZeneca, Bristol-Myers Squibb and AbbVie go deeper in this FREE webinar series
  2. Syndax Pharmaceuticals' leukaemia drug Revuforj bags FDA approval The therapeutic is the first and only menin inhibitor to gain FDA approval for acute relapsed or refractory acute leukaemia
  3. AbbVie's Elahere approved for platinum-resistant ovarian cancer by the European Commission Elahere is the first FRα-targeting antibody-drug conjugate (ADC) to be approved in Europe for platinum-resistant ovarian cancer
  4. Cleancube multi: Guardtech’s container facilities support NHS aseptic pharmacies Award-winning mobile cleanrooms offer fast, flexible solutions for facility upgrades
  5. Merck attains $588m global license for PD-1/VEGF bispecific antibody from LaNova Medicines The bispecific antibody is designed for oncological indications and functions by inhibiting the PD-1/PD-L1 and the VEGF/VEGFR receptor signalling pathways

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Regulatory

Fresenius Kabi receives approval for tocilizumab biosimilar Tyenne

The Interleukin-6 antagonist can be used to treat various inflammatory and immune mediated conditions
Manufacturing

AGC to support Pfizer-BioNTech Omicron vaccine

Plasmid DNA from AGC is already supplied as a starting material for the companies' COVID-19 vaccine
Ingredients

Pfizer and BioNTech announce early positive vaccine update

Collaboration has announced results from German Phase 1/2 COVID-19 vaccine study, including first T-Cell response data
Finance

BioNTech completes acquisition of Neon Therapeutics

Biopharmaceutical New Technologies (BioNTech) is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases
Ingredients

Vifor Pharma enters Chinese joint venture with Fresenius Kabi

Joint venture will bring IV Iron to China to replace the wasteful blood transfusions that are the current prevailing treatment for iron deficiency anaemia
Design & Build

Fresenius Kabi to invest $250 million to expand Melrose Park site in Illinois, US

Building work will start next year at generic injectables plant and will be completed in 2026
Research & Development

Fresenius Medical Care establishes regenerative medicine subsidiary

Unicyte will continue successful work with University of Turin into kidney and liver diseases, diabetes and cancer
Subscribe now